Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Two better than one where lowering blood pressure is concerned

15.03.2004


A new set of guidelines for lowering blood pressure has been published by the British Hypertension Society (BHS) today. Their main recommendation is that most people with hypertension should be on two blood pressure lowering drugs rather than one.



The guidelines which are aimed at UK doctors, are published in summary form in the BMJ today (12 March), and represent best practice in treating UK patients for hypertension.

People with a blood pressure higher than 140/90 (mm Hg) are classified as having high blood pressure or hypertension.


Some 42 per cent of people in the UK aged between 35 and 64 are estimated to have hypertension, which puts them at a greatly increased risk of heart attacks and strokes.

Basing their guidelines on new data from clinical trials and safety tests of anti-hypertensive drugs, the guidelines say that for the best results in the UK, doctors must aim to get the blood pressure of their patients as low as possible, and for many that means taking a combination of the presently available drugs.

BHS President, Professor Neil Poulter of Imperial College London and St Mary’s hospital, Paddington, and co-author of the BMJ paper said:

"We suggest that two-thirds of people with hypertension should be on two drugs not one to get them down to their target blood pressure.

"But we know that 60 per cent of people on treatment for hypertension are receiving just one blood pressure lowering drug, meaning that many people are missing out on what we consider the best standard of treatment in this country.

The guidelines, authored by the Guidelines Committee of the British Hypertension Society, also suggest a simple ’AB/CD protocol’ to help doctors combine the different classes of blood pressure lowering drugs to provide the best treatment.

For those under 55, they say start with an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker, and then if the target lower blood pressure is not reached, to use either a Calcium channel inhibitor or a Diruretic in addition, until the target is reached.

For those over 55, they suggest starting with a Calcium channel inhibitor or a Diruretic first, and if the target lower blood pressure is not reached, to use an ACE Inhibitor (or an Angiotensin receptor blocker) or a Beta blocker in addition.

For black patients they recommend using the same protocol as suggested for those over 55, regardless of patient’s age, as the ’C and D’ drugs are more effective on older people and in the black population than ’A and B’ drugs. This is because older people and black people have less natural renin than non-black (white and asian) and younger people, and C and D drugs work better than A and B where renin levels are low.

The BHS guidelines were last revised in 1999. Specialists in the field representing over 12 different stakeholder organisations including the British Hearth Foundation, the Royal College of General Practitioners and the UK Department of Health contributed to the latest guidelines.


For further information, please contact:

Professor Neil Poulter
International Centre for Circulatory Health
Imperial College London and St Mary’s Hospital, London
Tel: 44-207-594-3446
Email: n.poulter@imperial.ac.uk

Tony Stephenson
Imperial College London Press Office
Tel: 44-207-594-6712
Mobile: 44-775-373-9766
E-mail: at.stephenson@imperial.ac.uk

Tony Stephenson | alfa
Further information:
http://www.imperial.ac.uk
http://www.bmj.com

More articles from Health and Medicine:

nachricht Chronic stress induces fatal organ dysfunctions via a new neural circuit
21.08.2017 | Hokkaido University

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Nagoya physicists resolve long-standing mystery of structure-less transition

21.08.2017 | Materials Sciences

Chronic stress induces fatal organ dysfunctions via a new neural circuit

21.08.2017 | Health and Medicine

Scientists from the MSU studied new liquid-crystalline photochrom

21.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>